keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KRFK TFA, a TSP-1-derived peptide, activates TGF-β and enhances its associated signaling pathways independently of thrombospondin (TSP) receptors like CD47 and CD36. This compound has potential applications in research on chronic ocular surface inflammatory disorders [1].
Description | KRFK TFA, a TSP-1-derived peptide, activates TGF-β and enhances its associated signaling pathways independently of thrombospondin (TSP) receptors like CD47 and CD36. This compound has potential applications in research on chronic ocular surface inflammatory disorders [1]. |
In vitro | KRFK TFA (50 μM; 24 h) activates TGF-β secretion and reduces the expression of dendritic cell maturation markers in TSP-1-deficient bone marrow-derived dendritic cells (BMDCs) [1]. |
In vivo | KRFK TFA (administered as a single dose of 5 μg/5 µL to one eye) significantly prevented the development of chronic ocular surface inflammation in TSP-1 -/- mice [1]. |
Molecular Weight | N/A |
Formula | C27H47N9O5.xC2HF3O2 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.